Top Page
Smith & Nephew Snats
(NYSE:SNN)
Smith & Nephew Snats (SNN) vs. SPDR S&P 500 ETF (SPY)
Smith & Nephew Snats Business Overview & Revenue Model
Smith & Nephew Snats Key Performance Indicators (KPIs)
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
The FlySmith & Nephew Snats Earnings Call Summary
Smith & Nephew Snats Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.97B | 5.81B | 5.55B | 5.21B | 5.21B | 4.56B |
| Gross Profit | 4.18B | 4.05B | 3.82B | 3.67B | 3.67B | 3.16B |
| EBITDA | 1.44B | 1.24B | 956.00M | 874.00M | 1.24B | 866.00M |
| Net Income | 493.64M | 412.00M | 263.00M | 223.00M | 524.00M | 448.00M |
Balance Sheet | ||||||
| Total Assets | 10.68B | 10.35B | 9.99B | 9.97B | 10.92B | 11.01B |
| Cash, Cash Equivalents and Short-Term Investments | 675.41M | 619.00M | 302.00M | 350.00M | 1.29B | 1.76B |
| Total Debt | 3.45B | 3.32B | 3.08B | 2.87B | 3.34B | 3.69B |
| Total Liabilities | 5.15B | 5.09B | 4.77B | 4.71B | 5.35B | 5.73B |
| Stockholders Equity | 5.53B | 5.26B | 5.22B | 5.26B | 5.57B | 5.28B |
Cash Flow | ||||||
| Free Cash Flow | 799.32M | 606.00M | 181.00M | 110.00M | 469.00M | 492.00M |
| Operating Cash Flow | 1.15B | 987.00M | 608.00M | 468.00M | 877.00M | 935.00M |
| Investing Cash Flow | -345.22M | -569.00M | -448.00M | -472.00M | -691.00M | -606.00M |
| Financing Cash Flow | -676.96M | -86.00M | -200.00M | -926.00M | -645.00M | 1.16B |
Smith & Nephew Snats Technical Analysis
Smith & Nephew Snats Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $50.63B | 48.26 | 10.43% | ― | 0.19% | 65.58% | |
72 Outperform | $148.11B | 46.13 | 15.08% | 0.95% | 10.95% | -18.32% | |
71 Outperform | $125.95B | 27.26 | 9.38% | 2.76% | 5.34% | 13.15% | |
69 Neutral | $14.94B | 32.64 | 9.20% | 2.28% | 5.78% | 61.52% | |
68 Neutral | $113.10B | 39.30 | 12.60% | ― | 21.62% | 54.80% | |
65 Neutral | $19.47B | 27.74 | 5.60% | 1.05% | 5.47% | -23.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Smith & Nephew Snats Corporate Events
On 12 January 2026, Smith+Nephew announced the acquisition of US-based Integrity Orthopaedics, an early-stage commercial developer of the Tendon Seam rotator cuff repair system, in a deal worth up to $450 million, including an initial $225 million in cash and performance-based payments over five years. The Tendon Seam technology, which received FDA 510(k) clearance in 2023, is designed to lower re-tear rates and simplify rotator cuff surgery in a US market estimated at $875 million, and will bolster Smith+Nephew’s already broad shoulder portfolio that includes the REGENETEN Bioinductive Implant, Q-FIX All-Suture Anchor and AETOS Shoulder System; financed from existing cash and expected to be accretive to trading profit margins by 2028 while keeping leverage below 2x EBITDA, the deal advances the company’s RISE growth strategy and strengthens its bid for global leadership in sports medicine shoulder repair.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
As of 31 December 2025, Smith & Nephew plc reported a total issued share capital of 877,724,845 ordinary shares of US$0.20 each, of which 27,963,140 are held in treasury, leaving 849,761,705 ordinary shares with voting rights. The company stated on 2 January 2026 that this voting share count should be used by investors as the denominator when assessing whether they must disclose holdings or changes in holdings under the UK Financial Conduct Authority’s disclosure and transparency rules, clarifying the reference base for regulatory notifications and shareholder reporting obligations.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On December 8, 2025, Smith+Nephew announced its new RISE strategy and financial targets for 2028 at its Capital Markets Day in London. The strategy aims to elevate financial and operational performance, focusing on reaching more patients, innovating product offerings, scaling operations, and executing efficiently. The company updated its 2025 full-year guidance, expecting a trading profit margin of at least 19.5% and free cash flow around $800 million. Smith+Nephew also plans to rationalize its product portfolio, estimating a $200 million non-cash inventory provision in 2025 to simplify offerings and improve capital efficiency. The RISE strategy is expected to deliver significant shareholder value and solidify Smith+Nephew’s leadership in healthcare innovation.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Smith & Nephew Snats, a company listed on the London Stock Exchange, announced that as of November 30, 2025, its total issued share capital consists of 877,724,845 ordinary shares, with 28,000,826 held in treasury. This results in 849,724,019 ordinary shares with voting rights, which shareholders should use as the denominator for determining their interests according to the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Smith & Nephew plc announced on November 19, 2025, that key executives participated in the company’s Employee Stock Purchase Plan, acquiring American Depositary Shares through the Dividend Re-Investment Plan after the interim dividend payment on November 7, 2025. This transaction, conducted on the New York Stock Exchange, underscores the company’s commitment to aligning managerial interests with shareholder value, potentially enhancing stakeholder confidence.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Smith & Nephew plc, a UK-based company, reported a change in major holdings due to an acquisition or disposal of voting rights by BlackRock, Inc. On November 14, 2025, BlackRock’s voting rights in Smith & Nephew reached a total of 7.17%, with 5.01% attached to shares and 2.16% through financial instruments. This change was officially notified on November 17, 2025.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On November 11, 2025, Smith & Nephew plc announced the vesting of 3,016 restricted shares awarded to CEO Deepak Nath under an agreement from April 2022. A portion of these shares was sold to meet tax obligations, reflecting the company’s adherence to regulatory requirements and impacting its financial disclosures. This transaction, conducted on the London Stock Exchange, underscores the company’s commitment to transparent governance and may influence stakeholder perceptions regarding executive compensation practices.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On November 10, 2025, Smith & Nephew plc, a UK-based company, reported a change in major holdings due to an acquisition or disposal of voting rights by BlackRock, Inc. The notification revealed that BlackRock’s voting rights in Smith & Nephew decreased slightly from 7.18% to 7.17%, with a total of 60,996,414 voting rights held. This adjustment in holdings reflects a minor shift in BlackRock’s investment position, which could have implications for the company’s influence over Smith & Nephew’s strategic decisions.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On November 7, 2025, Smith & Nephew plc announced the purchase of ordinary shares through its Dividend Re-Investment Plan following the interim dividend payment. This transaction, disclosed under the UK Market Abuse Regulation, involved key executives, including the CEO and presidents of various divisions, purchasing shares at a price of £12.4048 each. This move reflects the company’s commitment to aligning managerial interests with shareholder value, potentially impacting its market position positively.
The most recent analyst rating on (SNN) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On November 6, 2025, Smith & Nephew plc announced a significant transaction involving the purchase of American Depositary Shares (ADS) by Ajay Dhankhar, the Chief Corporate Strategy & Development Officer, on the New York Stock Exchange. This transaction, disclosed under the UK Market Abuse Regulation, highlights the company’s ongoing strategic activities and could indicate confidence in the company’s future performance, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SNN) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Smith & Nephew plc, a company operating in the medical technology industry, announced a transaction involving the purchase of American Depositary Shares (ADS) by KAGAMA Family Investments, LP, which is closely associated with Garheng Kong, an Independent Non-Executive Director. The transaction, which took place on November 6, 2025, at the New York Stock Exchange, involved the purchase of 3,000 ADS at a price of $33.9773 each. This notification is made in compliance with the UK Market Abuse Regulation, reflecting the company’s commitment to transparency in its financial dealings.
The most recent analyst rating on (SNN) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Smith+Nephew has announced the appointment of Thérèse Esperdy as an independent Non-Executive Director and Senior Independent Director designate, effective December 1, 2025. Esperdy, who brings extensive experience from her roles in financial services and as a board member of international businesses, will succeed Angie Risley following the company’s AGM in May 2026. This strategic appointment is expected to enhance the company’s governance and strengthen its board with Esperdy’s expertise, particularly in highly regulated industries.
The most recent analyst rating on (SNN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Smith & Nephew reported a 5.0% underlying revenue growth in the third quarter of 2025, with total revenue reaching $1,501 million. The company highlighted strong performance in its orthopaedics, sports medicine, and advanced wound management divisions, driven by new product launches and strategic initiatives. The company maintained its full-year revenue and profit margin outlook while raising its free cash flow guidance to $750 million, reflecting improved operational efficiency. A $500 million share buyback was completed, showcasing robust cash generation. Smith & Nephew’s strategic focus on innovation and product launches continues to bolster its market position and drive growth.
The most recent analyst rating on (SNN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Smith & Nephew reported a 5.0% underlying revenue growth in the third quarter of 2025, with a total revenue of $1,501 million, driven by strong performance in orthopaedics, sports medicine, and advanced wound management. The company has completed a $500 million share buyback and raised its free cash flow guidance to $750 million, reflecting robust cash generation and operational efficiency. New product launches, such as the CORIOGRAPH Pre-Op Planning and Modeling Services and the CENTRIO PRP System, have contributed significantly to revenue growth, supporting the company’s strategic goals and enhancing its market position.
The most recent analyst rating on (SNN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On October 31, 2025, Smith & Nephew plc reported its total issued share capital, comprising 877,724,845 ordinary shares, with 29,017,524 held in treasury. This results in 848,707,321 shares with voting rights, a crucial figure for shareholders under the FCA’s Disclosure Guidance and Transparency Rules. This announcement ensures transparency and aids stakeholders in understanding their voting power and obligations.
The most recent analyst rating on (SNN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On October 22, 2025, BlackRock, Inc. crossed a significant threshold in its voting rights in Smith & Nephew, reaching a total of 7.18%. This change in holdings, notified on October 23, 2025, reflects a slight increase from their previous position and could impact Smith & Nephew’s shareholder dynamics and influence within the company.
The most recent analyst rating on (SNN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Smith & Nephew plc, a global medical technology company, announced that an interim dividend of 15.0 US cents per ordinary share will be paid on November 7, 2025. Shareholders in the UK or those who opted for sterling dividends will receive 11.26 pence per share. This announcement, initially made on August 5, 2025, reflects the company’s ongoing commitment to returning value to its shareholders.
The most recent analyst rating on (SNN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On October 16, 2025, Smith & Nephew plc released its six-monthly block listing return, detailing the status of various share schemes from February 1 to July 31, 2025. The report highlights that the Global Share Plan 2010 saw 206 securities issued, leaving 3,756 unallotted, while the Global Share Plan 2020 issued 5,758 securities, with 403,258 remaining unallotted. Other schemes, such as the Smith & Nephew ShareSave Plan and International ShareSave Plan, reported no new issuances, maintaining their previous balances. This update provides stakeholders with insights into the company’s equity distribution and potential future financial strategies.
The most recent analyst rating on (SNN) stock is a Hold with a $37.50 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On October 13, 2025, BlackRock, Inc., a major shareholder, adjusted its voting rights in Smith & Nephew plc, resulting in a new total of 7.17% of voting rights. This change, notified on October 14, 2025, reflects a slight increase from the previous total of 6.76%, indicating a strategic adjustment in BlackRock’s investment in the company. The adjustment in voting rights could influence Smith & Nephew’s governance and strategic decisions, impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SNN) stock is a Hold with a $37.50 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.